Neurexis Therapeutics, Inc. — Form D
Neurexis Therapeutics, Inc. of AURORA, CO, a company, filed a Form D exempt-offering notice with the SEC on 2022-05-23. The offering totals $200K, of which $55K was reported sold. Industry: Other.
Offering
- Filed: 2022-05-23
- Form: D
- Accession: 0001849201-22-000001
- Industry: Other
- Exemptions: 06b
- Total offering: $200K
- Amount sold: $55K
- Remaining: $145K
- Investors: 1
- Date of first sale: 2022-05-18
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-446621
Issuer
- Name: Neurexis Therapeutics, Inc.
- CIK: 0001849201
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 12635 E MOUNTVIEW BLVD., AURORA, CO, 80045
- Phone: 4795712592
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Michael Calvin Artinger | Director | Fort Collins, CO |
| K. Ulrich Bayer | Director | Aurora, CO |
| Robert Calvin Goforth | Director | Fayetteville, AR |
| Michael Calvin Artinger | Executive Officer | Fort Collins, CO |
| Michael Artinger | Director | Fayetteville, AR |
| Michael Artinger | Executive Officer | Fayetteville, AR |
| Ulrich Calvin Bayer | Director | Fayetteville, AR |
| Ulli Calvin Bayer | Director | Fayetteville, AR |
Other filings by this issuer (2)
More